^
Association details:
Biomarker:PLCD1 deleltion
Cancer:Non Small Cell Lung Cancer
Drug Class:PD-L1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer

Excerpt:
At the focal level, we found that loss of tumor-suppressor genes, such as integrin α9 (ITGA9) and phospholipase Cδ1 (PLCD1), were among the top individual CNA events that significantly correlated with a worse outcome following anti–PD-(L)1 treatment.
DOI:
10.1158/1078-0432.CCR-19-0585